Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ischemix, a biotechnology company, has appointed Robert DuFresne as its new CEO. Mr DuFresne has served on Ischemix's board of directors since May 2007 and will continue in this role moving forward.
Subscribe to our email newsletter
Most recently, Mr DuFresne served as president and CEO of Pacgen Biopharmaceuticals. Prior to that, Mr DuFresne served as president and CEO of Zelos Therapeutics and ConjuChem and held the positions of president and COO at Anika Therapeutics and senior vice president of business development at Alpha Beta Technology.
Reinier Beeuwkes, prior CEO of Ischemix, will continue to advise the company as president and chairman.
Mr DuFresne said: “I am thrilled to join Ischemix at such an exciting juncture in the company’s history. I look forward to working with the talented scientific and business team at Ischemix to advance the company’s novel pipeline, including the initiation of Phase IIa clinical proof of concept studies for CMX-2043 this summer.”